Health Related Quality of Life in Adult Low and High-Grade Glioma Patients Using the National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS) and Neuro-QOL Assessments
Health Related Quality of Life in Adult Low and High-Grade Glioma Patients Using the National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS) and Neuro-QOL Assessments
复制标题
DOI：
10.3389/fneur.2019.00212
复制
发表时间：
2019-03-15
影响因子：
3.4
通讯作者：
Hervey-Jumper, Shawn L.
中科院分区：
文献类型：
--
作者：
Gabel, Nicolette;Altshuler, David B.;Hervey-Jumper, Shawn L.
在研究和临床实践环境中，健康相关的生活质量(HRQOL)测量在胶质瘤患者的管理中变得越来越重要。功能障碍在低级别和高级别胶质瘤患者中很常见，因为这种疾病既有肿瘤学表现，也有神经系统表现。自然病史以及内科或外科治疗都会对HRQOL产生负面影响。对于胶质瘤患者的HRQOL评估没有统一的标准。在这项研究中，我们考察了患者对功能结果领域的看法，并使用美国国立卫生研究院(NIH)患者报告结果测量信息系统(PROIS)和神经生活质量题库作为HRQOL的衡量标准，报告了损害率的流行情况。对79名胶质瘤患者前瞻性收集的数据集的回顾分析显示，在80.7%的患者中，生活质量问题是做出治疗决定的最重要考虑因素。PROMIS和神经生活质量评估的功能损害发生率较高，在身体功能领域为28.6%，在认知功能领域为43.9%。与HGG患者相比，LGG患者与身体衰退相关的疼痛和焦虑程度更高。失语症的严重程度也会影响HRQOL。这项研究的结果表明，PROMIS和神经生活质量评估可能是未来在更大的临床研究和临床试验环境中使用的重要的HRQOL指标。
Health related quality of life (HRQOL) measures have become increasingly important in the management of glioma patients in both research and clinical practice settings. Functional impairment is common in low-grade and high-grade glioma patients as the disease has both oncological and neurological manifestations. Natural disease history as well as medical or surgical treatment can negatively influence HRQOL. There are no universal standards for HRQOL assessment in glioma patients. In this study, we examine patient perspectives on functional outcome domains and report the prevalence of impairments rates using the National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS) and Neuro-QOL item banks as measures of HRQOL. Retrospective analysis of a prospectively collected dataset involving 79 glioma patients reveals that quality of life concerns are the most important consideration behind making decisions about treatment in 80.7% of patients. The prevalence of functional impairment by PROMIS and NEURO-QOL assessment is high, ranging from 28.6% in the physical function domain to 43.9% in the cognitive function domain. Pain and anxiety related to physical decline is higher in LGG patients compared to HGG patients. Aphasia severity also impacts HRQOL. The results of this study suggest that the PROMIS and NEURO-QOL assessments may be important HRQOL metrics for future use in larger clinical research and clinical trial settings.